Table of Content - Tumor Ablation Market Size, Share, Trends Report 2032

Tumor Ablation market Segmentation

Tumor Ablation Technology Outlook (USD Billion, 2018-2030)

Radiofrequency

Microwave

Irreversible Electroporation

Cryoablation

Tumor Ablation Treatment Outlook (USD Billion, 2018-2030)

Surgical Ablation

Percutaneous Ablation

Laparoscopic Ablation

Tumor Ablation Application Outlook (USD Billion, 2018-2030)

Lung Cancer

Kidney Cancer

Liver Cancer

Tumor Ablation End User Outlook (USD Billion, 2018-2030)

Hospitals & Clinics

Specialty Centers

Tumor Ablation Regional Outlook (USD Billion, 2018-2030)

North America Outlook (USD Billion, 2018-2030)
- North America Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- North America Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- North America Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- North America Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- US Outlook (USD Billion, 2018-2030)
- US Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- US Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- US Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- US Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- CANADA Outlook (USD Billion, 2018-2030)
- CANADA Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- CANADA Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- CANADA Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- CANADA Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers

Europe Outlook (USD Billion, 2018-2030)
- Europe Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- Europe Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- Europe Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- Europe Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- Germany Outlook (USD Billion, 2018-2030)
- Germany Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- Germany Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- Germany Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- Germany Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- France Outlook (USD Billion, 2018-2030)
- France Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- France Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- France Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- France Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- UK Outlook (USD Billion, 2018-2030)
- UK Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- UK Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- UK Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- UK Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- ITALY Outlook (USD Billion, 2018-2030)
- ITALY Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- ITALY Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- ITALY Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- ITALY Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- SPAIN Outlook (USD Billion, 2018-2030)
- Spain Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- Spain Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- Spain Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- Spain Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- Rest Of Europe Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- REST OF EUROPE Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- REST OF EUROPE Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- REST OF EUROPE Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers

Asia-Pacific Outlook (USD Billion, 2018-2030)
- Asia-Pacific Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- Asia-Pacific Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- Asia-Pacific Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- Asia-Pacific Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- China Outlook (USD Billion, 2018-2030)
- China Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
  - China Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- China Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- China Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- Japan Outlook (USD Billion, 2018-2030)
- Japan Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- Japan Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- Japan Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- Japan Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- India Outlook (USD Billion, 2018-2030)
- India Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- India Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- India Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- India Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- Australia Outlook (USD Billion, 2018-2030)
- Australia Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- Australia Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- Australia Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- Australia Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)
- Rest of Asia-Pacific Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- Rest of Asia-Pacific Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- Rest of Asia-Pacific Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- Rest of Asia-Pacific Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers

Rest of the World Outlook (USD Billion, 2018-2030)
- Rest of the World Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- Rest of the World Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- Rest of the World Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- Rest of the World Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- Middle East Outlook (USD Billion, 2018-2030)
- Middle East Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- Middle East Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- Middle East Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- Middle East Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- Africa Outlook (USD Billion, 2018-2030)
- Africa Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- Africa Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- Africa Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- Africa Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers
- Latin America Outlook (USD Billion, 2018-2030)
- Latin America Tumor Ablation by Technology
  - Radiofrequency
  - Microwave
  - Irreversible Electroporation
  - Cryoablation
- Latin America Tumor Ablation by Treatment
  - Surgical Ablation
  - Percutaneous Ablation
  - Laparoscopic Ablation
- Latin America Tumor Ablation by Application
  - Lung Cancer
  - Kidney Cancer
  - Liver Cancer
- Latin America Tumor Ablation by End User
  - Hospitals & Clinics
  - Specialty Centers

Research Methodology on Tumor Ablation Market

1. Introduction

The tumor ablation market is a global source for research and development activities related to the use of ablation therapy for tumors such as the liver, lung, kidney, and prostate. It is segmented into both internal and external ablation techniques, product and service-related developments, research trials, case studies, and regional market analysis to provide information about the device types, ablation techniques, therapeutic outcomes, and safety profiles. This research provides an overview of the current market trends and estimates associated with tumor ablation technology and provides both qualitative and quantitative insights into the market. The study focuses on the key market dynamics, industry size, revenue, and geographical trends.

2. Research Objectives and Goals

The primary goal of this research is to provide a comprehensive overview of the current state of the tumor ablation market. In particular, the research seeks to provide a market size, segmentation, and scenario analysis and identify potential opportunities for market expansion in the future. In addition, the research identifies the current and future trends in the tumor ablation market and the associated challenges to global market participants. The scope of the research includes insights into the market overview, technology and product ideation, clinical and economic analysis, market adoption, clinical trial and regulatory developments, major players and their strategies, and global market opportunities and challenges.

3. Research methodology

This research is based on a comprehensive and extensive market research methodology, supplemented with secondary research, industry interviews and data analysis to obtain detailed insights into the tumor ablation market. For this purpose, we have adopted both primary and secondary research sources, including in-depth interviews with industry participants, customized surveys and macro-economic trends. Various secondary sources, such as white papers and market data, are used to provide a comprehensive view of the tumor ablation market. The analysis is supplemented with a thorough assessment of the economic, socio-economic, political and technological aspects of the global tumor ablation market. Additionally, in-depth interviews with industry participants have been conducted to gain insights into their opinion and views on the current and future scenarios for the market.

4. Research Framework

The research framework consists of the following steps:

Market Overview: In the market overview step, the research team will provide an overview of the market, including its current state and development, with a focus on drivers, restraints and opportunities associated with the growing adoption of tumor ablation technology globally.

Market Segmentation: The segmentation step involves the identification and classification of different segments related to the tumor ablation market, such as technology, product type, patient population, therapeutic application, and regional demand.

Market Dynamics: This step includes the identification and analysis of the current and emerging trends associated with the global tumor ablation market.

Market Scenario: The market scenario step involves a thorough assessment of the overall market dynamics, including insights into the competitive landscape, patent analysis, and regulatory framework.

Research & Development: The research & development step includes the identification and evaluation of recent product innovations and research developments related to the tumor ablation market.

Business & Regulatory Environment: This step involves the identification and analysis of the key regulatory frameworks, current market trends and economic analysis of the tumor ablation market.

5. Data Collection Methodology

The research is based on both primary and secondary sources of research. For the primary research, interviews were conducted with key industry participants, such as manufacturers, distributors and end users, to obtain a comprehensive understanding of the current and future scenarios for the market. The industry interviews were conducted through telephonic interviews, online survey forms and in-person meetings. To obtain insights into the latest market trends and developments, the research team employed both primary and secondary research processes. Secondary sources, such as published reports and white papers, were extensively used to obtain a detailed understanding of the market.

6. Data Analysis Methodology

The research team used both quantitative and qualitative analyses to obtain a comprehensive understanding of the tumor ablation market. Both primary and secondary sources of data were used to quantify and analyze the data. Quantitative analyses include market scenario assessment, segmentation, market size estimation and market forecast using a combination of regression, qualitative and quantitative methods.

To supplement the primary and secondary sources, in-depth interviews were conducted with industry participants, such as manufacturers, distributors and end users. The research team also conducted a thorough market analysis to identify the competitive landscape, market dynamics and key industry trends.

7. Conclusion

This report is a comprehensive overview of the tumor ablation market, which details its current development and future prospects. Through data collection, analysis and market assessment, the report provides extensive insight into the evolution of the tumor ablation market and its key strategies and strategies. The report provides an extensive understanding of the current market dynamics, key players, technology advancements and opportunities for expansion for the global tumor ablation market.

Leading companies partner with us for data-driven Insights

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 15

1.1.1 MARKET SYNOPSIS 15

2 MARKET INTRODUCTION 16

2.1 SCOPE OF THE STUDY 16

2.2 RESEARCH OBJECTIVE 16

2.3 LIST OF ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY 18

3.1 DATA MINING 18

3.2 SECONDARY RESEARCH 19

3.3 PRIMARY RESEARCH 20

3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 20

3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS 21

3.4 FORECASTING TECHNIQUES 21

3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22

3.5.1 BOTTOM-UP APPROACH 23

3.5.2 TOP-DOWN APPROACH 24

3.6 DATA TRIANGULATION 24

3.7 VALIDATION 24

4 MARKET DYNAMICS 26

4.1 OVERVIEW 26

4.2 DRIVERS 27

4.2.1 INCREASING PREVALENCE OF CANCER ACROSS THE GLOBE 27

4.2.2 RISING DEMAND FOR MINIMALLY INVASIVE TUMOR ABLATION TECHNIQUES 27

4.2.3 GROWING NUMBER OF PUBLIC-PRIVATE INITIATIVES AND FUNDING TO SUPPORT ONGOING RESEARCH ACTIVITIES RELATED TO TUMOR ABLATION 27

4.3 RESTRAINTS 28

4.3.1 SIDE-EFFECTS AND COMPLICATIONS ASSOCIATED WITH TUMOR ABLATION 28

4.3.2 DELAY IN APPROVAL AND UNFAVORABLE REGULATORY POLICY AND REIMBURSEMENT SCENARIO 28

4.4 OPPORTUNITY 29

4.4.1 RISING R&D ACTIVITIES 29

5 MARKET FACTOR ANALYSIS 30

5.1 VALUE CHAIN ANALYSIS 30

5.1.1 R&D 31

5.1.2 MANUFACTURING 31

5.1.3 DISTRIBUTION & SALES 31

5.1.4 POST-SALES MONITORING 31

5.2 PORTER'S FIVE FORCES ANALYSIS 32

5.2.1 THREAT OF NEW ENTRANTS 33

5.2.2 BARGAINING POWER OF SUPPLIERS 33

5.2.3 BARGAINING POWER OF BUYERS 33

5.2.4 THREAT OF SUBSTITUTES 33

5.2.5 INTENSITY OF RIVALRY 33

5.3 COVID-19 IMPACT ANALYSIS 34

5.3.1 IMPACT ON AVAILABILITY OF SURGICAL FACILITIES 34

5.3.2 IMPACT ON KEY PLAYERS 34

5.3.3 IMPACT ON CLINICAL TRIALS 35

5.3.4 IMPACT ON SUPPLY CHAIN 35

6 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY 36

6.1 OVERVIEW 36

6.2 RADIOFREQUENCY 37

6.3 MICROWAVE 37

6.4 IRREVERSIBLE ELECTROPORATION 38

6.5 CRYOABLATION 39

6.6 OTHERS 40

7 GLOBAL TUMOR ABLATION MARKET, BY TREATMENT 41

7.1 OVERVIEW 41

7.2 SURGICAL ABLATION 42

7.3 PERCUTANEOUS ABLATION 42

7.4 LAPAROSCOPIC ABLATION 43

8 GLOBAL TUMOR ABLATION MARKET, BY APPLICATION 44

8.1 OVERVIEW 44

8.2 LUNG CANCER 45

8.3 KIDNEY CANCER 45

8.4 LIVER CANCER 46

8.5 OTHERS 47

9 GLOBAL TUMOR ABLATION MARKET, BY END USER 48

9.1 OVERVIEW 48

9.2 HOSPITAL AND CLINICS 49

9.3 SPECIALITY CENTERS 50

9.4 OTHERS 50

10 GLOBAL TUMOR ABLATION MARKET, BY REGION 51

10.1 OVERVIEW 51

10.2 NORTH AMERICA 52

10.2.1 US 55

10.2.2 CANADA 56

10.3 EUROPE 58

10.3.1 GERMANY 61

10.3.2 FRANCE 62

10.3.3 UK 63

10.3.4 ITALY 65

10.3.5 SPAIN 66

10.3.6 REST OF EUROPE 67

10.4 ASIA PACIFIC 69

10.4.1 CHINA 71

10.4.2 INDIA 72

10.4.3 JAPAN 74

10.4.4 SOUTH KOREA 75

10.4.5 AUSTRALIA 76

10.4.6 REST OF ASIA PACIFIC 78

10.5 REST OF THE WORLD 80

10.5.1 MIDDLE EAST 82

10.5.2 AFRICA 84

10.5.3 LATIN AMERICA 85

11 COMPETITIVE LANDSCAPE 87

11.1 OVERVIEW 87

11.2 COMPETITIVE BENCHMARKING 88

11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL TUMOR ABLATION MARKET 89

11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL TUMOR ABLATION MARKET 90

11.5 KEY DEVELOPMENT ANALYSIS 90

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 91

11.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 91

11.6.2 MERGER &ACQUISITION 91

11.7 FINANCIAL MATRIX 92

11.7.1 SALES (USD MILLION), 2020 92

11.7.2 R&D EXPENDITURE (USD MILLION), 2020 92

12 DRG COST OF CURATIVE TREATMENT 93

12.1 DIAGNOSIS-RELATED GROUP (DRG) 93

12.2 BIOPSY PROCEDURE REIMBURSEMENT 93

12.3 ABLATION PROCEDURE REIMBURSMENT 93

12.3.1 LIVER ABLATION PROCEDURE REIMBURSMENT 94

12.3.2 KIDNEY ABLATION PROCEDURE REIMBURSMENT 94

12.3.3 LUNG ABLATION PROCEDURE REIMBURSMENT 95

12.4 IMAGING PROCEDURE REIMBURSMENT 95

12.5 TOTAL CURATIVE TREATMENT COSTS 96

13 COMPANY PROFILES 97

13.1 SONACARE MEDICAL 97

13.1.1 COMPANY OVERVIEW 97

13.1.2 FINANCIAL OVERVIEW 97

13.1.3 PRODUCTS/SERVICES OFFERED 97

13.1.4 KEY DEVELOPMENTS 97

13.1.5 SWOT ANALYSIS 98

13.1.6 KEY STRATEGIES 98

13.2 MEDTRONIC PLC 99

13.2.1 COMPANY OVERVIEW 99

13.2.2 FINANCIAL OVERVIEW 99

13.2.3 PRODUCTS/SERVICES OFFERED 100

13.2.4 KEY DEVELOPMENTS 100

13.2.5 SWOT ANALYSIS 100

13.2.6 KEY STRATEGIES 101

13.3 EDAP TMS 102

13.3.1 COMPANY OVERVIEW 102

13.3.2 FINANCIAL OVERVIEW 102

13.3.3 PRODUCTS/SERVICES OFFERED 103

13.3.4 KEY DEVELOPMENTS 103

13.3.5 SWOT ANALYSIS 103

13.3.6 KEY STRATEGIES 103

13.4 ANGIODYNAMICS 104

13.4.1 COMPANY OVERVIEW 104

13.4.2 FINANCIAL OVERVIEW 104

13.4.3 PRODUCTS/SERVICES OFFERED 105

13.4.4 KEY DEVELOPMENTS 105

13.4.5 SWOT ANALYSIS 105

13.4.6 KEY STRATEGIES 105

13.5 HEALTHTRONICS, INC. 106

13.5.1 COMPANY OVERVIEW 106

13.5.2 FINANCIAL OVERVIEW 106

13.5.3 PRODUCTS/SERVICES OFFERED 106

13.5.4 KEY DEVELOPMENTS 106

13.5.5 SWOT ANALYSIS 107

13.5.6 KEY STRATEGIES 107

13.6 JOHNSON & JOHNSON 108

13.6.1 COMPANY OVERVIEW 108

13.6.2 FINANCIAL OVERVIEW 108

13.6.3 PRODUCTS/SERVICES OFFERED 109

13.6.4 KEY DEVELOPMENTS 109

13.6.5 SWOT ANALYSIS 109

13.6.6 KEY STRATEGIES 109

13.7 BOSTON SCIENTIFIC CORPORATION 110

13.7.1 COMPANY OVERVIEW 110

13.7.2 FINANCIAL OVERVIEW 110

13.7.3 PRODUCTS/SERVICES OFFERED 111

13.7.4 KEY DEVELOPMENTS 111

13.7.5 SWOT ANALYSIS 111

13.7.6 KEY STRATEGIES 112

13.8 MISONIX, INC. 113

13.8.1 COMPANY OVERVIEW 113

13.8.2 FINANCIAL OVERVIEW 113

13.8.3 PRODUCTS/SERVICES OFFERED 114

13.8.4 KEY DEVELOPMENTS 114

13.8.5 SWOT ANALYSIS 114

13.8.6 KEY STRATEGIES 115

13.9 HISTOSONICS, INC. 116

13.9.1 COMPANY OVERVIEW 116

13.9.2 FINANCIAL OVERVIEW 116

13.9.3 PRODUCTS/SERVICES OFFERED 116

13.9.4 KEY DEVELOPMENTS 116

13.9.5 SWOT ANALYSIS 117

13.9.6 KEY STRATEGIES 117

13.10 BIOTRONIK 118

13.10.1 COMPANY OVERVIEW 118

13.10.2 FINANCIAL OVERVIEW 118

13.10.3 PRODUCTS/SERVICES OFFERED 118

13.10.4 KEY DEVELOPMENTS 118

13.10.5 SWOT ANALYSIS 119

13.10.6 KEY STRATEGIES 119

14 APPENDIX 120

14.1 REFERENCES 120

14.2 RELATED REPORTS 120

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16

TABLE 2 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 36

TABLE 3 GLOBAL TUMOR ABLATION MARKET, FOR RADIOFREQUENCY, BY REGION, 2022–2030 (USD MILLION) 37

TABLE 4 GLOBAL TUMOR ABLATION MARKET, FOR MICROWAVE, BY REGION, 2022–2030 (USD MILLION) 38

TABLE 5 GLOBAL TUMOR ABLATION MARKET, FOR IRREVERSIBLE ELECTROPORATION, BY REGION, 2022–2030 (USD MILLION) 38

TABLE 6 GLOBAL TUMOR ABLATION MARKET, FOR CRYOABLATION, BY REGION, 2022–2030 (USD MILLION) 39

TABLE 7 GLOBAL TUMOR ABLATION MARKET, FOR OTHERS, BY REGION, 2022–2030 (USD MILLION) 40

TABLE 8 GLOBAL: TUMOR ABLATION MARKET, BY TREATMENT, 2022–2030 (USD MILLION) 41

TABLE 9 GLOBAL: TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY REGION, 2022–2030 (USD MILLION) 42

TABLE 10 GLOBAL: TUMOR ABLATION MARKET, FOR PERCUTANEOUS ABLATION, BY REGION, 2022–2030 (USD MILLION) 42

TABLE 11 GLOBAL: TUMOR ABLATION MARKET, FOR LAPAROSCOPIC ABLATION, BY REGION, 2022–2030 (USD MILLION) 43

TABLE 12 GLOBAL: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 44

TABLE 13 GLOBAL: TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2022–2030 (USD MILLION) 45

TABLE 14 5-YEAR RELATIVE SURVIVAL RATES FOR KIDNEY CANCER 46

TABLE 15 GLOBAL: TUMOR ABLATION MARKET, FOR KIDNEY CANCER, BY REGION, 2022–2030 (USD MILLION) 46

TABLE 16 GLOBAL: TUMOR ABLATION MARKET, FOR LIVER CANCER, BY REGION, 2022–2030 (USD MILLION) 47

TABLE 17 GLOBAL: TUMOR ABLATION MARKET, FOR OTHERS, BY REGION, 2022–2030 (USD MILLION) 47

TABLE 18 GLOBAL: TUMOR ABLATION MARKET, BY END USER, 2022–2030 (USD MILLION) 48

TABLE 19 GLOBAL: TUMOR ABLATION MARKET FOR HOSPITAL AND CLINICS, BY REGION, 2022–2030 (USD MILLION) 49

TABLE 20 GLOBAL: TUMOR ABLATION MARKET, FOR SPECIALITY CENTERS, BY REGION, 2022–2030 (USD MILLION) 50

TABLE 21 GLOBAL: TUMOR ABLATION MARKET FOR OTHERS, BY REGION, 2022–2030 (USD MILLION) 50

TABLE 22 GLOBAL: TUMOR ABLATION MARKET, BY REGION, 2022–2030 (USD MILLION) 51

TABLE 23 ESTIMATED NUMBER OF US CANCER SURVIVORS BY SITE (MALE), 2020 52

TABLE 24 ESTIMATED NUMBER OF US CANCER SURVIVORS BY SITE (FEMALE), 2020 53

TABLE 25 NORTH AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 53

TABLE 26 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 54

TABLE 27 NORTH AMERICA: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 54

TABLE 28 NORTH AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 54

TABLE 29 NORTH AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 55

TABLE 30 US: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 55

TABLE 31 US: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 55

TABLE 32 US: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 56

TABLE 33 US: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 56

TABLE 34 CANADA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 56

TABLE 35 CANADA: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 57

TABLE 36 CANADA: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 57

TABLE 37 CANADA: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 57

TABLE 38 EUROPE: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 59

TABLE 39 EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 59

TABLE 40 EUROPE: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 60

TABLE 41 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 60

TABLE 42 EUROPE: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 60

TABLE 43 GERMANY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 61

TABLE 44 GERMANY: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 61

TABLE 45 GERMANY: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 61

TABLE 46 GERMANY: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 62

TABLE 47 FRANCE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 62

TABLE 48 FRANCE: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 62

TABLE 49 FRANCE: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 63

TABLE 50 FRANCE: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 63

TABLE 51 UK: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 63

TABLE 52 UK: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 64

TABLE 53 UK: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 64

TABLE 54 UK: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 64

TABLE 55 ITALY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 65

TABLE 56 ITALY: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 65

TABLE 57 ITALY: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 65

TABLE 58 ITALY: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 66

TABLE 59 SPAIN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 66

TABLE 60 SPAIN: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 66

TABLE 61 SPAIN: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 67

TABLE 62 SPAIN: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 67

TABLE 63 REST OF EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 67

TABLE 64 REST OF EUROPE: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 68

TABLE 65 REST OF EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 68

TABLE 66 REST OF EUROPE: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 68

TABLE 67 ASIA PACIFIC: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 69

TABLE 68 ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 70

TABLE 69 ASIA PACIFIC: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 70

TABLE 70 ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 70

TABLE 71 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 71

TABLE 72 CHINA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 71

TABLE 73 CHINA: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 71

TABLE 74 CHINA: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 72

TABLE 75 CHINA: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 72

TABLE 76 INDIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 72

TABLE 77 INDIA: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 73

TABLE 78 INDIA: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 73

TABLE 79 INDIA: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 73

TABLE 80 JAPAN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 74

TABLE 81 JAPAN: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 74

TABLE 82 JAPAN: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 74

TABLE 83 JAPAN: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 75

TABLE 84 SOUTH KOREA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 75

TABLE 85 SOUTH KOREA: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 75

TABLE 86 SOUTH KOREA: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 76

TABLE 87 SOUTH KOREA: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 76

TABLE 88 AUSTRALIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 76

TABLE 89 AUSTRALIA: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 77

TABLE 90 AUSTRALIA: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 77

TABLE 91 AUSTRALIA: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 77

TABLE 92 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 78

TABLE 93 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 78

TABLE 94 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 78

TABLE 95 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 79

TABLE 96 REST OF THE WORLD: TUMOR ABLATION MARKET, BY REGION, 2022–2030 (USD MILLION) 80

TABLE 97 REST OF THE WORLD: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 81

TABLE 98 REST OF THE WORLD: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 81

TABLE 99 REST OF THE WORLD: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 82

TABLE 100 REST OF THE WORLD: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 82

TABLE 101 MIDDLE EAST: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 82

TABLE 102 MIDDLE EAST: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 83

TABLE 103 MIDDLE EAST: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 83

TABLE 104 MIDDLE EAST: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 83

TABLE 105 AFRICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 84

TABLE 106 AFRICA: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 84

TABLE 107 AFRICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 84

TABLE 108 AFRICA: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 85

TABLE 109 LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 85

TABLE 110 LATIN AMERICA: TUMOR ABLATION MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 85

TABLE 111 LATIN AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 86

TABLE 112 LATIN AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022-2030 (USD MILLION) 86

TABLE 113 MAJOR PLAYERS IN THE GLOBAL TUMOR ABLATION MARKET 87

TABLE 114 MOST ACTIVE PLAYER IN THE GLOBAL TUMOR ABLATION MARKET 90

TABLE 115 PRODUCT LAUNCH/PRODUCT APPROVAL 91

TABLE 116 MERGER &ACQUISITION 91

TABLE 117 BIOPSY PROCEDURE REIMBURSEMENT (USD), 2019 93

TABLE 118 LIVER ABLATION PROCEDURE REIMBURSMENT (USD), 2019 94

TABLE 119 KIDNEY ABLATION PROCEDURE REIMBURSMENT (USD), 2019 94

TABLE 120 LUNG ABLATION PROCEDURE REIMBURSMENT 95

TABLE 121 IMAGING PROCEDURE REIMBURSMENT 95

TABLE 122 TOTAL CURATIVE TREATMENT COSTS 96

TABLE 123 SONACARE MEDICAL: PRODUCTS/SERVICES OFFERED 97

TABLE 124 SONACARE MEDICAL: KEY DEVELOPMENTS 97

TABLE 125 MEDTRONIC PLC: PRODUCTS/SERVICES OFFERED 100

TABLE 126 EDAP TMS: PRODUCTS/SERVICES OFFERED 103

TABLE 127 ANGIODYNAMICS: PRODUCTS/SERVICES OFFERED 105

TABLE 128 HEALTHTRONICS, INC.: PRODUCTS/SERVICES OFFERED 106

TABLE 129 JOHNSON & JOHNSON: PRODUCTS/SERVICES OFFERED 109

TABLE 130 BOSTON SCIENTIFIC CORPORATION: PRODUCTS/SERVICES OFFERED 111

TABLE 131 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENTS 111

TABLE 132 MISONIX, INC.: PRODUCTS/SERVICES OFFERED 114

TABLE 133 MISONIX, INC.: KEY DEVELOPMENTS 114

TABLE 134 HISTOSONICS, INC.: PRODUCTS/SERVICES OFFERED 116

TABLE 135 BIOTRONIK: PRODUCTS/SERVICES OFFERED 118

LIST OF FIGURES

FIGURE 1 GLOBAL TUMOR ABLATION MARKET STRUCTURE 17

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 23

FIGURE 3 MARKET DYNAMICS ANALYSIS OF THE GLOBAL TUMOR ABLATION MARKET 26

FIGURE 4 DRIVERS: IMPACT ANALYSIS 28

FIGURE 5 RESTRAINTS: IMPACT ANALYSIS 29

FIGURE 6 VALUE CHAIN ANALYSIS: GLOBAL TUMOR ABLATION MARKET 30

FIGURE 7 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL TUMOR ABLATION MARKET 32

FIGURE 8 GLOBAL TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY, 2020-2030 (USD MILLION) 36

FIGURE 9 GLOBAL: TUMOR ABLATION MARKET, BY TREATMENT, 2022 & 2030 (USD MILLION) 41

FIGURE 10 GLOBAL: TUMOR ABLATION MARKET, BY APPLICATION, 2022 & 2030 (USD MILLION) 44

FIGURE 11 GLOBAL: TUMOR ABLATION MARKET, BY END USER, 2022 & 2030 (USD MILLION) 48

FIGURE 12 GLOBAL: TUMOR ABLATION MARKET, BY REGION 2022 & 2030 (USD MILLION) 51

FIGURE 13 NORTH AMERICA: TUMOR ABLATION MARKET SHARE, BY COUNTRY 2020 (%) 53

FIGURE 14 EUROPE, NUMBER OF NEW CANCER CASES IN 2020 58

FIGURE 15 EUROPE: TUMOR ABLATION MARKET SHARE (%), BY COUNTRY, 2020 59

FIGURE 16 ASIA PACIFIC: TUMOR ABLATION MARKET SHARE (%), BY REGION, 2020 69

FIGURE 17 REST OF THE WORLD, NUMBER OF NEW CANCER CASES IN 2020 80

FIGURE 18 REST OF THE WORLD: TUMOR ABLATION MARKET SHARE (%), BY REGION, 2020 81

FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS 88

FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL TUMOR ABLATION MARKET 89

FIGURE 21 GLOBAL TUMOR ABLATION MARKET: COMPETITIVE LANDSCAPE 90

FIGURE 22 SALES (USD MILLION), 2020 92

FIGURE 23 R&D EXPENDITURE (USD MILLION), 2020 92

FIGURE 24 SONACARE MEDICAL: SWOT ANALYSIS 98

FIGURE 25 MEDTRONIC PLC: FINANCIAL OVERVIEW SNAPSHOT 99

FIGURE 26 MEDTRONIC PLC: SWOT ANALYSIS 100

FIGURE 27 EDAP TMS: FINANCIAL OVERVIEW SNAPSHOT 102

FIGURE 28 EDAP TMS: SWOT ANALYSIS 103

FIGURE 29 ANGIODYNAMICS: FINANCIAL OVERVIEW SNAPSHOT 104

FIGURE 30 ANGIODYNAMICS: SWOT ANALYSIS 105

FIGURE 31 HEALTHTRONICS, INC.: SWOT ANALYSIS 107

FIGURE 32 JOHNSON & JOHNSON: FINANCIAL OVERVIEW SNAPSHOT 108

FIGURE 33 JOHNSON & JOHNSON: SWOT ANALYSIS 109

FIGURE 34 BOSTON SCIENTIFIC CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 110

FIGURE 35 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS 111

FIGURE 36 MISONIX, INC.: FINANCIAL OVERVIEW SNAPSHOT 113

FIGURE 37 MISONIX, INC.: SWOT ANALYSIS 114

FIGURE 38 HISTOSONICS, INC.: SWOT ANALYSIS 117

FIGURE 39 BIOTRONIK: SWOT ANALYSIS 119

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

FEATURES	LICENCE TYPE
FEATURES	Single User	Multiuser Licence	Enterprise User
Price	$ 4,950	$ 5,950	$ 7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout The Organization.
Free Customization
Direct access to the Analyst
Deliverable Format
Deliverable Format
Platform Access
Discount on Your Next Purchase	10%	15%	10%
Printable Versions

Why Choose Market Research Future?

Leading companies partner with us for data-driven Insights